Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C

A Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Lomitapide in Japanese and Caucasian Volunteers With Elevated Low-density-lipoprotein(LDL-C)

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of orally administered lomitapide in healthy male Japanese and Caucasian subjects with elevated LDL-C. The purpose for this study is to evaluate the PK and PD of lomitapide in Japanese subjects as compared to Caucasian subjects.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteer
• Intervention / Treatment: Drug: lomitapide

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Surrey
    • Croydon, Surrey, United Kingdom, CR7 7YE
      • Richmond Pharmacology Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 1. Subject is a healthy male or female, Caucasian or Japanese, aged 20 - 45 years, inclusive, at screening.

  2. Subject has a BMI of 18.5 - 30 kg/m2 inclusive at screening.

  3. Subjects must have a screening LDL-C measurement and the mean of Day 5 and Day 6 measurements greater than or equal to 110mg/dL.

  4. Subjects must agree to use acceptable methods of contraception (details provided in the protocol)

  5. Subjects must be capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form prior to undergoing any study-related procedures.

Exclusion Criteria:

1. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion.
2. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission.
3. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) which in the opinion of the Investigator is clinically relevant or will interfere with the ECG analysis.
4. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological, psychiatric or other disease.
5. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg), anti-Hepatitis core antibody (anti-HBc Ig G [and anti-HBc IgM if IgG is positive], Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2) at screening.
6. Confirmed positive results from urine drug screen or from the alcohol breath test at screening and on admission (Day -1).
7. History or clinical evidence of alcohol or drug abuse.
8. Mentally handicapped.
9. Participation in a drug trial within 90 days prior to first drug administration.
10. Use of any medication (including over-the-counter (OTC) medication) within 2 weeks prior to admission (Day -1) or within less than 10 times the elimination half-life of the respective drug, or anticipated concomitant medication during the treatment periods.
11. Use of any substance inhibiting CYP3A4 enzymes within 2 weeks prior to admission (Day -1).
12. Donation of more than 500 mL of blood within 90 days prior to drug administration.
13. Subjects who smoke more than 10 cigarettes or equivalent amount of tobacco per day and/or who cannot stop smoking for the duration of the study whilst in the CPU.
14. Treatment with herbal supplements during the 7 days prior to dosing, or use of vitamins during 48 hours prior to admission (Day -1).
15. Any circumstances or conditions, which, in the opinion of the PI, may affect full participation in the trial or compliance with the protocol.
16. Legal incapacity or limited legal capacity at screening.
17. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with the study standardised menus.
18. If female, subject was pregnant or lactating (females of child bearing potential must have negative pregnancy tests at screening and admission).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; 12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive 10 mg lomitapide and 2 will receive placebo.	Drug: lomitapide
Experimental: Cohort 2; 8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 20 mg lomitapide and 2 will receive placebo.	Drug: lomitapide
Experimental: Cohort 3; 8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 40 mg lomitapide and 2 will receive placebo.	Drug: lomitapide
Experimental: Cohort 4; 8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 60 mg lomitapide and 2 will receive placebo.	Drug: lomitapide

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax for Lomitapide	Maximum observed plasma concentration for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
Tmax for Lomitapide	Time to maximum observed concentration for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
AUC0-t for Lomitapide	Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
AUC0-∞ for Lomitapide	Area under the plasma concentration versus time curve from zero to infinity for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
t1/2 for Lomitapide	Apparent terminal elimination half-life for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
Cmax for Lomitapide	Maximum observed plasma concentration for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
Tmax for Lomitapide	Time to maximum observed concentration for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
AUC0-t for Lomitapide	Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
t1/2 for Lomitapide	Apparent terminal elimination half-life for lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax for M1	Maximum observed plasma concentration for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
Tmax for M1	Time to maximum observed concentration for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
AUC0-t for M1	Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
AUC0-∞ for M1	Area under the plasma concentration versus time curve from zero to infinity for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
t1/2 for M1	Apparent terminal elimination half-life for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
Cmax for M3	Maximum observed plasma concentration for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
Tmax for M3	Time to maximum observed concentration for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
AUC0-t for M3	Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
AUC0-∞ for M3	Area under the plasma concentration versus time curve from zero to infinity for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
t1/2 for M3	Apparent terminal elimination half-life for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7
Cmax for M1	Maximum observed plasma concentration for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
Tmax for M1	Time to maximum observed concentration for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
AUC0-t for M1	Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
t1/2 for M1	Apparent terminal elimination half-life for M1 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
Cmax for M3	Maximum observed plasma concentration for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
Tmax for M3	Time to maximum observed concentration for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
AUC0-t for M3	Area under the plasma concentration versus time curve from hour 0 to the last measurable concentration for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27
t1/2 for M3	Apparent terminal elimination half-life for M3 metabolite of lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27

Collaborators and Investigators

• Sponsor: Aegerion Pharmaceuticals, Inc.
• Collaborators: Richmond Pharmacology Limited

Study record dates

Study Major Dates

• Study Start (Actual): November 7, 2012
• Primary Completion (Actual): June 3, 2013
• Study Completion (Actual): June 3, 2013

Study Registration Dates

• First Submitted: November 21, 2012
• First Submitted That Met QC Criteria: January 3, 2013
• First Posted (Estimate): January 4, 2013

Study Record Updates

• Last Update Posted (Actual): November 20, 2018
• Last Update Submitted That Met QC Criteria: November 16, 2018
• Last Verified: November 1, 2018

More Information

Terms related to this study

• Other Study ID Numbers: AEGR-733-023; 2012-004220-37 (EudraCT Number)